Peter Kolchinsky portfolio, Q2 2025
RA Capital Management · 13F for the quarter ending Jun 30, 2025
For Q2 2025, RA Capital Management reported $5.9B across 63 US-listed positions, led by ASND (29.9%), PCVX (6.6%) and RYTM (5.9%). Compared with its filing for Q1 2025, Peter Kolchinsky opened 6 new positions, added to 9, reduced 9 and sold out of 28; 39 positions did not change.
The largest purchase was an addition to Cidara Therapeutics Inc ($110.7M); the largest sale, the sale of the whole position in Apogee Therapeutics Inc ($58.6M).
Key facts
- 13F portfolio value
- $5.9BQ2 2025
- Positions
- 63
- Largest holding
- ASND 29.9%
- New positions
- 6
- Sold out
- 28
- Filed
- Aug 14, 2025
Holdings as of (Q2 2025), filed with the SEC on . Changes are measured against the filing for Mar 31, 2025. Every tracked investor's Q2 2025 13F.
Bought and sold in Q2 2025
| Stock | Move | Shares | Size | Of portfolio |
|---|---|---|---|---|
Cidara Therapeutics Incno ticker on file | ▲ Added 208% | +2.27M | $110.7M | 1.87% |
Apogee Therapeutics Incno ticker on file | ▼ Sold out | −1.57M | $58.6M | 0.99% |
| Zai Lab LtdZLAB | ▼ Sold out | −1.3M | $46.8M | 0.79% |
Day One Biopharmaceuticalsno ticker on file | ▼ Sold out | −5.76M | $45.6M | 0.77% |
| UroGen Pharma LtdURGN | ▼ Sold out | −3.21M | $35.5M | 0.60% |
| Rhythm Pharmaceuticals IncRYTM | ▼ Reduced 8.6% | −523.05K | $33.1M | 0.56% |
| Taysha Gene Therapies IncTSHA | ▲ Added 117% | +12.68M | $29.3M | 0.49% |
Avidity Biosciences Incno ticker on file | ▲ Added 15% | +965.62K | $27.4M | 0.46% |
Astria Therapeutics Incno ticker on file | ▼ Sold out | −5.11M | $27.3M | 0.46% |
| Kura Oncology IncKURA | ▼ Sold out | −4M | $26.4M | 0.45% |
Aerovate Therapeutics Incno ticker on file | ▼ Sold out | −9.19M | $23.1M | 0.39% |
| IDEAYA Biosciences IncIDYA | ▼ Sold out | −1.35M | $22.1M | 0.37% |
Iteos Therapeutics Incno ticker on file | ▼ Sold out | −3.65M | $21.8M | 0.37% |
| Glaukos CorpGKOS | ▼ Sold out | −190.26K | $18.7M | 0.32% |
| Eyepoint Pharmaceuticals IncEYPT | ▼ Sold out | −3.18M | $17.2M | 0.29% |
| 10X Genomics IncTXG | ▼ Reduced 76% | −1.47M | $17M | 0.29% |
| Ceribell IncCBLL | ▼ Sold out | −824.58K | $15.8M | 0.27% |
| Nurix Therapeutics IncNRIX | ▼ Sold out | −1.33M | $15.8M | 0.27% |
| Hinge Health IncHNGE | ▲ New | +300K | $15.5M | 0.26% |
| Insmed IncINSM | ▼ Sold out | −200K | $15.3M | 0.26% |
| Tyra Biosciences IncTYRA | ▲ Added 15% | +1.56M | $14.9M | 0.25% |
| Edgewise Therapeutics IncEWTX | ▲ Added 11% | +993.54K | $13M | 0.22% |
| MBX Biosciences IncMBX | ▼ Reduced 75% | −1.13M | $12.9M | 0.22% |
| Alector IncALEC | ▼ Sold out | −9.7M | $11.9M | 0.20% |
| Sera Prognostics IncSERA | ▼ Sold out | −3.03M | $11.2M | 0.19% |
| Jade Biosciences IncJBIO | ▲ New | +1.06M | $10.6M | 0.18% |
| Tango Therapeutics IncTNGX | ▲ New | +2M | $10.2M | 0.17% |
| Bicycle Therapeutics PlcBCYC | ▼ Sold out | −1.09M | $9.3M | 0.16% |
| GH Research PLCGHRS | ▲ Added 11% | +732.05K | $8.9M | 0.15% |
| Immatics N.V.IMTX | ▼ Sold out | −1.75M | $7.9M | 0.13% |
| Bright Minds Biosciences IncDRUG | ▼ Sold out | −206.43K | $7.4M | 0.13% |
| Omada Health IncOMDA | ▲ New | +400K | $7.3M | 0.12% |
| Vaxcyte IncPCVX | ▼ Reduced 1.8% | −223.16K | $7.3M | 0.12% |
| Solid Biosciences IncSLDB | ▲ Added 34% | +1.48M | $7.2M | 0.12% |
| Protara Therapeutics IncTARA | ▼ Reduced 69% | −2.36M | $7.2M | 0.12% |
| Aclaris Therapeutics IncACRS | ▼ Sold out | −4.67M | $7.1M | 0.12% |
| Xencor IncXNCR | ▼ Sold out | −575K | $6.1M | 0.10% |
| Humacyte IncHUMA | ▼ Sold out | −3.31M | $5.6M | 0.10% |
| GeneDx Holdings CorpWGS | ▲ New | +58.04K | $5.4M | 0.09% |
| Zura Bio LtdZURA | ▼ Sold out | −3.22M | $4.2M | 0.07% |
| Bioage Labs IncBIOA | ▼ Sold out | −1.05M | $4M | 0.07% |
| CytomX Therapeutics IncCTMX | ▲ Added 166% | +1.66M | $3.8M | 0.06% |
| Boundless Bio IncBOLD | ▼ Sold out | −2.18M | $3.3M | 0.06% |
| Acadia Healthcare CompanyACHC | ▼ Reduced 59% | −127.74K | $2.9M | 0.05% |
| Sutro BiopharmaSTRO | ▼ Sold out | −4.43M | $2.9M | 0.05% |
| Lexeo Therapeutics IncLXEO | ▼ Sold out | −546.55K | $1.9M | 0.03% |
| Inflarx NVIFRX | ▲ New | +1.97M | $1.6M | 0.03% |
| Surrozen IncSRZN | ▼ Reduced 11% | −76.5K | $683.9K | 0.01% |
| Werewolf Therapeutics IncHOWL | ▲ Added 8.7% | +536.43K | $584.7K | 0.01% |
| RxSight IncRXST | ▼ Reduced 1.1% | −40.05K | $520.7K | 0.01% |
Scilex Holding Cono ticker on file | ▼ Sold out | −1.04M | $257.5K | 0.00% |
| Avalo Therapeutics IncAVTX | ▼ Reduced 3.5% | −34.03K | $169.8K | 0.00% |
Holdings at the quarter's end
| # | Stock | Sector | Share of portfolio | Value | Shares | Reported price | Held | Since Q1 2025 |
|---|---|---|---|---|---|---|---|---|
| 1 | Ascendis Pharma A/SASND · SPONSORED ADR | Health Care | 29.9% | $1.8B | 10.28M | $172.60 | 5+ qtrs | No change |
| 2 | Vaxcyte IncPCVX | Health Care | 6.55% | $389M | 11.97M | $32.51 | 5+ qtrs | ▼ Reduced 1.8% |
| 3 | Rhythm Pharmaceuticals IncRYTM | Health Care | 5.92% | $351.4M | 5.56M | $63.19 | 5+ qtrs | ▼ Reduced 8.6% |
| 4 | Janux Therapeutics IncJANX | — | 4.36% | $258.5M | 11.19M | $23.10 | 5+ qtrs | No change |
| 5 | Avidity Biosciences Incno ticker on file · SH | — | 3.48% | $206.4M | 7.27M | $28.40 | 5+ qtrs | ▲ Added 15% |
| 6 | Arcellx Incno ticker on file · SH | — | 3.37% | $200M | 3.04M | $65.85 | 5+ qtrs | No change |
| 7 | 89BIO Incno ticker on file · SH | — | 3.29% | $195.3M | 19.89M | $9.82 | 5+ qtrs | No change |
| 8 | Ars Pharmaceuticals IncSPRY | — | 3.19% | $189.5M | 10.86M | $17.45 | 5+ qtrs | No change |
| 9 | Newamsterdam Pharma CompanyNAMS | — | 3.09% | $183.6M | 10.14M | $18.11 | 5+ qtrs | No change |
| 10 | Sionna Therapeutics IncSION | — | 3.05% | $181.2M | 10.45M | $17.35 | 2 qtrs | No change |
| 11 | Cidara Therapeutics Incno ticker on file · SH | — | 2.76% | $163.9M | 3.37M | $48.71 | 4 qtrs | ▲ Added 208% |
| 12 | Edgewise Therapeutics IncEWTX | Health Care | 2.19% | $129.8M | 9.9M | $13.11 | 5+ qtrs | ▲ Added 11% |
| 13 | Lenz Therapeutics IncLENZ | — | 2.06% | $122.5M | 4.18M | $29.31 | 5+ qtrs | No change |
| 14 | Wave Life Sciences LtdWVE | — | 1.99% | $118.3M | 18.2M | $6.50 | 5+ qtrs | No change |
| 15 | Tyra Biosciences IncTYRA | — | 1.97% | $116.7M | 12.2M | $9.57 | 5+ qtrs | ▲ Added 15% |
| 16 | GH Research PLCGHRS | — | 1.58% | $93.6M | 7.68M | $12.19 | 5+ qtrs | ▲ Added 11% |
| 17 | Dyne Therapeutics IncDYN · SH | — | 1.56% | $92.5M | 9.71M | $9.52 | 5+ qtrs | No change |
| 18 | Geron CorpGERN | — | 1.43% | $85.1M | 60.38M | $1.41 | 5+ qtrs | No change |
| 19 | Disc Medicine IncIRON | — | 1.41% | $83.5M | 1.58M | $52.96 | 2 qtrs | No change |
| 20 | Mineralys Therapeutics IncMLYS | — | 1.40% | $83.2M | 6.15M | $13.53 | 5+ qtrs | No change |
| 21 | Septerna IncSEPN | — | 1.25% | $73.9M | 7M | $10.57 | 3 qtrs | No change |
| 22 | Fulcrum Therapeutics IncFULC | — | 1.19% | $70.4M | 10.23M | $6.88 | 5+ qtrs | No change |
| 23 | Bicara Therapeutics IncBCAX | — | 1.09% | $64.6M | 6.96M | $9.29 | 4 qtrs | No change |
| 24 | Vor Biopharma IncVOR · SH | — | 1.08% | $64.2M | 39.65M | $1.62 | 5+ qtrs | No change |
| 25 | Taysha Gene Therapies IncTSHA | — | 0.92% | $54.4M | 23.56M | $2.31 | 5+ qtrs | ▲ Added 117% |
| 26 | Dianthus Therapeutics IncDNTH | Health Care | 0.90% | $53.4M | 2.87M | $18.63 | 5+ qtrs | No change |
| 27 | RxSight IncRXST · SH | — | 0.81% | $48.1M | 3.7M | $13.00 | 5+ qtrs | ▼ Reduced 1.1% |
| 28 | Tourmaline Bio Incno ticker on file · SH | — | 0.68% | $40.6M | 2.54M | $15.99 | 5+ qtrs | No change |
| 29 | Scholar Rock Holding CorpSRRK · SH | Health Care | 0.68% | $40.3M | 1.14M | $35.42 | 3 qtrs | No change |
| 30 | Climb Bio IncCLYM | — | 0.66% | $39M | 31.42M | $1.24 | 5+ qtrs | No change |
| 31 | Structure Therapeutics IncGPCR · SH | — | 0.53% | $31.5M | 1.52M | $20.74 | 5+ qtrs | No change |
| 32 | Solid Biosciences IncSLDB | — | 0.48% | $28.3M | 5.81M | $4.87 | 5+ qtrs | ▲ Added 34% |
| 33 | Metsera Incno ticker on file · SH | — | 0.32% | $19.2M | 675.53K | $28.45 | 2 qtrs | No change |
| 34 | Monopar Therapeutics IncMNPR | — | 0.31% | $18.3M | 511.21K | $35.78 | 3 qtrs | No change |
| 35 | Nkarta IncNKTX | — | 0.30% | $17.9M | 10.81M | $1.66 | 5+ qtrs | No change |
| 36 | Larimar Therapeutics IncLRMR · SH | — | 0.29% | $17.5M | 6.05M | $2.89 | 5+ qtrs | No change |
| 37 | Acumen Pharmaceuticals IncABOS | — | 0.29% | $17.3M | 14.93M | $1.16 | 5+ qtrs | No change |
| 38 | Enliven Therapeutics IncELVN · SH | — | 0.29% | $17M | 848.99K | $20.06 | 5+ qtrs | No change |
| 39 | Travere Therapeutics IncTVTX | Health Care | 0.29% | $17M | 1.15M | $14.80 | 3 qtrs | No change |
| 40 | 4D Molecular TherapeuticsFDMT | — | 0.29% | $16.9M | 4.56M | $3.71 | 5+ qtrs | No change |
| 41 | Hinge Health IncHNGE | Technology | 0.26% | $15.5M | 300K | $51.75 | 1 qtr | New |
| 42 | Artiva Biotherapeutics IncARTV | — | 0.25% | $14.9M | 9.85M | $1.51 | 4 qtrs | No change |
| 43 | Pepgen IncPEPG | — | 0.20% | $11.9M | 10.69M | $1.11 | 5+ qtrs | No change |
| 44 | Jade Biosciences IncJBIO | — | 0.18% | $10.6M | 1.06M | $9.99 | 1 qtr | New |
| 45 | Tango Therapeutics IncTNGX · SH | — | 0.17% | $10.2M | 2M | $5.12 | 1 qtr | New |
| 46 | Acrivon Therapeutics IncACRV | — | 0.17% | $9.9M | 8.34M | $1.19 | 5+ qtrs | No change |
| 47 | Eledon Pharmaceuticals IncELDN · SH | — | 0.16% | $9.7M | 3.57M | $2.71 | 3 qtrs | No change |
| 48 | Arcus Biosciences IncRCUS · SH | — | 0.16% | $9.3M | 1.14M | $8.14 | 2 qtrs | No change |
| 49 | Perceptive Cap Solutionsno ticker on file | — | 0.13% | $8M | 750K | $10.62 | 5+ qtrs | No change |
| 50 | Omada Health IncOMDA · SH | — | 0.12% | $7.3M | 400K | $18.30 | 1 qtr | New |
| 51 | Werewolf Therapeutics IncHOWL | — | 0.12% | $7.3M | 6.68M | $1.09 | 5+ qtrs | ▲ Added 8.7% |
| 52 | Beta Bionics IncBBNX · SH | — | 0.12% | $7.3M | 500K | $14.56 | 2 qtrs | No change |
| 53 | CytomX Therapeutics IncCTMX · SH | — | 0.10% | $6M | 2.66M | $2.27 | 2 qtrs | ▲ Added 166% |
| 54 | 10X Genomics IncTXG · SH | Health Care | 0.09% | $5.5M | 475.34K | $11.58 | 3 qtrs | ▼ Reduced 76% |
| 55 | Surrozen IncSRZN · SH | — | 0.09% | $5.4M | 602.63K | $8.94 | 5+ qtrs | ▼ Reduced 11% |
| 56 | GeneDx Holdings CorpWGS | — | 0.09% | $5.4M | 58.04K | $92.31 | 1 qtr | New |
| 57 | Avalo Therapeutics IncAVTX | — | 0.08% | $4.7M | 932.97K | $4.99 | 4 qtrs | ▼ Reduced 3.5% |
| 58 | Adicet Bio IncACET · SH | — | 0.08% | $4.6M | 7.54M | $0.6100 | 5+ qtrs | No change |
| 59 | MBX Biosciences IncMBX · SH | — | 0.07% | $4.3M | 377.84K | $11.41 | 4 qtrs | ▼ Reduced 75% |
| 60 | Protara Therapeutics IncTARA · SH | — | 0.05% | $3.1M | 1.04M | $3.03 | 5+ qtrs | ▼ Reduced 69% |
| 61 | Newamsterdam Pharma Co NV-27no ticker on file · WTS | — | 0.05% | $2.7M | 333.33K | $8.00 | 5+ qtrs | No change |
| 62 | Acadia Healthcare CompanyACHC · SH | — | 0.03% | $2M | 89.26K | $22.69 | 2 qtrs | ▼ Reduced 59% |
| 63 | Inflarx NVIFRX · SH | — | 0.03% | $1.6M | 1.97M | $0.7900 | 1 qtr | New |
By sector
| Sector | Share of portfolio | Value | Positions |
|---|---|---|---|
| Health Care | 46.5% | $2.8B | 8 |
| Technology | 0.26% | $15.5M | 1 |
| No sector on file | 53.2% | $3.2B | 54 |
Questions and answers
What did Peter Kolchinsky own in Q2 2025?
RA Capital Management's 13F for Q2 2025 lists 63 positions worth $5.9B. The largest: ASND (29.9%), PCVX (6.6%), RYTM (5.9%), JANX (4.4%), Avidity Biosciences Inc (3.5%).
What did Peter Kolchinsky buy in Q2 2025?
The largest purchases, by the shares bought at the quarter-end price the filing implies: Cidara Therapeutics Inc (added, $110.7M), TSHA (added, $29.3M), Avidity Biosciences Inc (added, $27.4M), HNGE (new, $15.5M), TYRA (added, $14.9M), EWTX (added, $13M).
What did Peter Kolchinsky sell in Q2 2025?
The largest sales: Apogee Therapeutics Inc (sold out, $58.6M), ZLAB (sold out, $46.8M), Day One Biopharmaceuticals (sold out, $45.6M), URGN (sold out, $35.5M), RYTM (reduced, $33.1M), Astria Therapeutics Inc (sold out, $27.3M).
When was this filing made?
RA Capital Management filed its 13F for the quarter ending Jun 30, 2025 on Aug 14, 2025. A 13F is due within 45 days of the quarter's end, so the positions were already weeks old when it became public.
Learn
Cite this page
Funkfolio, “Peter Kolchinsky portfolio, Q2 2025: RA Capital Management 13F holdings”, data as of 14 August 2025. https://funkfolio.com/gurus/peter-kolchinsky/2025-q2
Underlying data: SEC EDGAR, Form 13F-HR of RA Capital Management (CIK 1346824) for the period ending Jun 30, 2025.
Source: SEC EDGAR, Form 13F-HR for RA Capital Management (CIK 1346824), period ending Jun 30, 2025, filed Aug 14, 2025. Changes compare share counts with the filing for Mar 31, 2025; a share split in between is allowed for where one is on record. “Reported price” is a position's reported value divided by its shares. The size of a buy or sell is the change in shares at that price; a position sold out is sized at its value in the previous filing, and “of portfolio” sets the size against the $5.9B reported for this quarter. “Held” counts consecutive quarterly filings up to this one, out of the 5 looked at from here back. Sectors are those of the ranked companies on this site as they stand today. Not a live portfolio and not advice.